188 related articles for article (PubMed ID: 12846580)
1. Inhibition of c-src transcription by mithramycin: structure-activity relationships of biosynthetically produced mithramycin analogues using the c-src promoter as target.
Remsing LL; Bahadori HR; Carbone GM; McGuffie EM; Catapano CV; Rohr J
Biochemistry; 2003 Jul; 42(27):8313-24. PubMed ID: 12846580
[TBL] [Abstract][Full Text] [Related]
2. Intra- and intermolecular triplex DNA formation in the murine c-myb proto-oncogene promoter are inhibited by mithramycin.
Vigneswaran N; Thayaparan J; Knops J; Trent J; Potaman V; Miller DM; Zacharias W
Biol Chem; 2001 Feb; 382(2):329-42. PubMed ID: 11308031
[TBL] [Abstract][Full Text] [Related]
3. Mithramycin SK, a novel antitumor drug with improved therapeutic index, mithramycin SA, and demycarosyl-mithramycin SK: three new products generated in the mithramycin producer Streptomyces argillaceus through combinatorial biosynthesis.
Remsing LL; González AM; Nur-e-Alam M; Fernández-Lozano MJ; Braña AF; Rix U; Oliveira MA; Méndez C; Salas JA; Rohr J
J Am Chem Soc; 2003 May; 125(19):5745-53. PubMed ID: 12733914
[TBL] [Abstract][Full Text] [Related]
4. Influence of GC and AT specific DNA minor groove binding drugs on intermolecular triplex formation in the human c-Ki-ras promoter.
Vigneswaran N; Mayfield CA; Rodu B; James R; Kim HG; Miller DM
Biochemistry; 1996 Jan; 35(4):1106-14. PubMed ID: 8573565
[TBL] [Abstract][Full Text] [Related]
5. Mithramycin selectively inhibits collagen-alpha 1(I) gene expression in human fibroblast.
Nehls MC; Brenner DA; Gruss HJ; Dierbach H; Mertelsmann R; Herrmann F
J Clin Invest; 1993 Dec; 92(6):2916-21. PubMed ID: 7504695
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of p53-mediated transcriptional responses by mithramycin A.
Koutsodontis G; Kardassis D
Oncogene; 2004 Dec; 23(57):9190-200. PubMed ID: 15489892
[TBL] [Abstract][Full Text] [Related]
7. Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy.
Albertini V; Jain A; Vignati S; Napoli S; Rinaldi A; Kwee I; Nur-e-Alam M; Bergant J; Bertoni F; Carbone GM; Rohr J; Catapano CV
Nucleic Acids Res; 2006; 34(6):1721-34. PubMed ID: 16571899
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts.
Previdi S; Malek A; Albertini V; Riva C; Capella C; Broggini M; Carbone GM; Rohr J; Catapano CV
Gynecol Oncol; 2010 Aug; 118(2):182-8. PubMed ID: 20452660
[TBL] [Abstract][Full Text] [Related]
9. Differential inhibition of restriction enzyme cleavage by chromophore-modified analogues of the antitumour antibiotics mithramycin and chromomycin reveals structure-activity relationships.
Mansilla S; Garcia-Ferrer I; Méndez C; Salas JA; Portugal J
Biochem Pharmacol; 2010 May; 79(10):1418-27. PubMed ID: 20093108
[TBL] [Abstract][Full Text] [Related]
10. The aureolic acid family of antitumor compounds: structure, mode of action, biosynthesis, and novel derivatives.
Lombó F; Menéndez N; Salas JA; Méndez C
Appl Microbiol Biotechnol; 2006 Nov; 73(1):1-14. PubMed ID: 17013601
[TBL] [Abstract][Full Text] [Related]
11. Modulation of the activity of Sp transcription factors by mithramycin analogues as a new strategy for treatment of metastatic prostate cancer.
Malek A; Núñez LE; Magistri M; Brambilla L; Jovic S; Carbone GM; Morís F; Catapano CV
PLoS One; 2012; 7(4):e35130. PubMed ID: 22545098
[TBL] [Abstract][Full Text] [Related]
12. Structure of the human 5-HT7 receptor gene and characterization of its promoter region.
Laenen K; Haegeman G; Vanhoenacker P
Gene; 2007 Apr; 391(1-2):252-63. PubMed ID: 17321075
[TBL] [Abstract][Full Text] [Related]
13. Mithramycin inhibits etoposide resistance in glucose-deprived HT-29 human colon carcinoma cells.
Lee EM; Park HR; Hwang JH; Park DJ; Chang KS; Kim CJ
J Microbiol Biotechnol; 2007 Nov; 17(11):1856-61. PubMed ID: 18092471
[TBL] [Abstract][Full Text] [Related]
14. Sp1 and Sp3 transcription factors upregulate the proximal promoter of the human prostate-specific antigen gene in prostate cancer cells.
Shin T; Sumiyoshi H; Matsuo N; Satoh F; Nomura Y; Mimata H; Yoshioka H
Arch Biochem Biophys; 2005 Mar; 435(2):291-302. PubMed ID: 15708372
[TBL] [Abstract][Full Text] [Related]
15. Sp1 and Sp3 regulate basal transcription of the survivin gene.
Xu R; Zhang P; Huang J; Ge S; Lu J; Qian G
Biochem Biophys Res Commun; 2007 Apr; 356(1):286-92. PubMed ID: 17350596
[TBL] [Abstract][Full Text] [Related]
16. DNA binding characteristics of mithramycin and chromomycin analogues obtained by combinatorial biosynthesis.
Barceló F; Ortiz-Lombardía M; Martorell M; Oliver M; Méndez C; Salas JA; Portugal J
Biochemistry; 2010 Dec; 49(49):10543-52. PubMed ID: 21067184
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional activity and Sp 1/3 transcription factor binding to the P1 promoter sequences of the human AbetaH-J-J locus.
Feriotto G; Finotti A; Breveglieri G; Treves S; Zorzato F; Gambari R
FEBS J; 2007 Sep; 274(17):4476-90. PubMed ID: 17681019
[TBL] [Abstract][Full Text] [Related]
18. Mithramycin blocks protein binding and function of the SV40 early promoter.
Ray R; Snyder RC; Thomas S; Koller CA; Miller DM
J Clin Invest; 1989 Jun; 83(6):2003-7. PubMed ID: 2542379
[TBL] [Abstract][Full Text] [Related]
19. Mithramycin A inhibits DNA methyltransferase and metastasis potential of lung cancer cells.
Lin RK; Hsu CH; Wang YC
Anticancer Drugs; 2007 Nov; 18(10):1157-64. PubMed ID: 17893516
[TBL] [Abstract][Full Text] [Related]
20. Dimerization and DNA recognition rules of mithramycin and its analogues.
Weidenbach S; Hou C; Chen JM; Tsodikov OV; Rohr J
J Inorg Biochem; 2016 Mar; 156():40-7. PubMed ID: 26760230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
